Abstract: The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

Abstract: A server information handling system is secured by a bezel that couples to an access location, such as an air vent at a front or rear face of a housing. The bezel includes a security structure having a lock and configured to couple directly at the front face or with a bezel extension at the rear face so that the server information handling system can use the same bezel with both a front face or rear face rack mount. The bezel has a lock integrated with the security structure, an air filter that fits over the security structure to filter air flowing into the housing, and a filter brace that captures the air filter by coupling to the security structure over the air filter. The filter brace attaches and detaches at the security structure when the security structure locks a server information handling system housing so that the air filter can be changed while the housing remains secure.

Abstract: An electronic device may be provided with an antenna having a resonating element formed from a segment of peripheral conductive housing structures. A speaker may be aligned with first openings in the segment. A vent may be aligned with second openings in the segment. A connector may protrude through the segment. A trace combiner for the antenna may be patterned onto the speaker and may be coupled to the segment. Tuners for the antenna may be disposed on first and second flexible printed circuits that extend along opposing sides of the connector. The tuners may be controlled through the speaker. The second flexible printed circuit may extend along the vent. The vent may have a vent cowling with a cut-out region next to the tuner on the second flexible printed circuit.

Abstract: The disclosure provides, inter alia, breast cancer biomarkers, methods of detecting exhausted CD8+ T cells in breast cancer patients, methods of detecting CD26+CD4+ T cells in breast cancer patients, methods of treating breast cancer patients, and methods of identifying risk outcomes for breast cancer patients.

Abstract: Provided herein, inter alia, are methods and compositions for the treatment of cancer. The compositions include one or more anti-cancer agents and Clostridium butyricum. Administration of Clostridium butyricum can enhance the therapeutic effects of anti-cancer agents, thereby increasing the efficacy of said agents for cancer treatment.

Abstract: The disclosure provides, inter alia, methods of detecting IL-6 signaling activity in T cells in breast cancer patients, such as breast cancer patients in remission.

Abstract: The disclosure provides, inter alia, methods of detecting IL-6 signaling activity in T cells in breast cancer patients, such as breast cancer patients in remission.

Abstract: Described herein, inter alia, are macrocyclic lactones such as ivermectin and methods for their use in treating, for example, hyperproliferative disorders such as cancer.

Abstract: Gene expression analysis is generally performed on heterogeneous tissue samples consisting of multiple cell types. Current methods developed to separate heterogeneous gene expression rely on prior knowledge of the cell-type composition and/or signatures—these are not available in most public datasets. We present a novel method to identify the cell-type composition, signatures and proportions per sample without need for a priori information. The method was successfully tested on controlled and semi-controlled datasets and performed as accurately as current methods that do require additional information. As such, this method enables the analysis of cell-type specific gene expression using existing large pools of publically available microarray datasets.

Abstract: Provided herein are methods of detecting cytokine signaling responsiveness in immune cells from a cancer subject and determining risk of relapse of cancer in a subject. The methods include isolating cells from a blood sample from the cancer subject thereby forming an isolated blood cell fraction that includes isolated blood sample cells, mixing the isolated blood sample cells with a cytokine, where the cytokine is selected from TGF?, IL-10, IL-4 and IFN?, and detecting the responsiveness of the isolated blood sample cells to the cytokine.

Abstract: The disclosure provides, inter alia, methods of detecting IL-6 signaling activity in T cells in breast cancer patients, such as breast cancer patients in remission.

Abstract: The disclosure provides, inter alia, methods of detecting IL-6 signaling activity in T cells in breast cancer patients, such as breast cancer patients in remission.

Abstract: The disclosure provides, inter alia, methods of detecting IL-6 signaling activity in T cells in breast cancer patients, such as breast cancer patients in remission.

Abstract: Described herein, inter alia, are macrocyclic lactones such as ivermectin and methods for their use in treating, for example, hyperproliferative disorders such as cancer.

Abstract: An in vitro assay is provided for determining the effect of an immune cell on a cell from an infectious or neoplastic disease. Also provided is an in vitro assay for determining the effect of an activated CD8+ T-cell on a sensitized melanoma cell. A method for improving the specific cytolytic activity (SCA) of an immune cell comprising contacting an immune cell with an antigen and an antigen-independent pro-inflammatory agent is provided. A method for ex vivo expansion of antigen-specific CD8+ T-cells with enhanced specific cytolytic activity (SCA) comprising culturing the antigen-specific CD8+ T-cells in a suitable culture media comprising an amino acid. An in vitro assay is provided for determining the effect of an immune cell on a cell from an infectious or neoplastic disease. A method of treating a subject suffering from an infectious or neoplastic disease with immuno therapy is described.

Abstract: Gene expression analysis is generally performed on heterogeneous tissue samples consisting of multiple cell types. Current methods developed to separate heterogeneous gene expression rely on prior knowledge of the cell-type composition and/or signatures—these are not available in most public datasets. We present a novel method to identify the cell-type composition, signatures and proportions per sample without need for a priori information. The method was successfully tested on controlled and semi-controlled datasets and performed as accurately as current methods that do require additional information. As such, this method enables the analysis of cell-type specific gene expression using existing large pools of publically available microarray datasets.

Abstract: Methods and compositions for producing target cell reactive lymphocytes, e.g., cytolytic T-lymphocytes, in a subject are provided. In practicing the subject methods, a lymphocyte population is contacted with an effective amount of a target cell peptide mixture of active and inactive peptides to produce lymphocytes reactive, e.g., cytolytic, for the target cell. Also provided are compositions, kits, and systems for practicing the subject methods. The subject invention finds use in a variety of different applications, including therapeutic applications.

Abstract: Methods and compositions for producing target cell reactive lymphocytes, e.g., cytolytic T-lymphocytes, in a subject are provided. In practicing the subject methods, a lymphocyte population is contacted with an effective amount of a target cell peptide mixture of active and inactive peptides to produce lymphocytes reactive, e.g., cytolytic, for the target cell. Also provided are compositions, kits, and systems for practicing the subject methods. The subject invention finds use in a variety of different applications, including therapeutic applications.

Abstract: This invention relates to methods of increasing the half-life of a viral-specific ligand on a mucosal membrane by modifying the viral-specific ligand to bind the bacteria colonized on the mucosal membrane. The invention also provides a chimeric molecule comprising a viral-specific ligand and a bacterial-specific ligand.

Abstract: This invention relates to methods of increasing the half-life of a viral-specific ligand on a mucosal membrane by modifying the viral-specific ligand to bind the bacteria colonized on the mucosal membrane. The invention also provides a chimeric molecule comprising a viral-specific ligand and a bacterial-specific ligand.